ClinicalTrials.gg
RecruitingNCT06439771Updated Oct 14, 2026

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

A Phase 2 interventional study of YL202 should be intravenously infused in Locally Advanced or Metastatic Breast Cancer, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 6 months later.
Updated Oct 14, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
635th of 1,519
180 · median 120
Started
2024
with 221 others
Phase 2
493 of 1,928
243 open now
Primary completion
2027-07
later than 689 of 1,063 live
Registered
1,314th of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 635th largest by planned enrollment of the 1,519 interventional ones that give a count, is one of 222 that started in 2024, is one of 493 in phase 2, reaches primary completion later than 689 of the 1,063 other live ones, and was the 1,314th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

861 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression

03

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have been informed of the study before the start of the study and voluntarily sign name and date on the form.
  2. Patients with locally advanced or disease (according to the UICC and AJCC staging system [Version 8]) who are not candidates for curative surgery or radiotherapy.
  3. Patients who are confirmed advanced/unresectable or metastatic breast cancer with HR-negative and -negative,.
  4. Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression.
  5. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC.
  6. Have at least 1 extracranial as a target lesion per (RECIST) v1.1
  7. Have Adequate organ and bone marrow function within 7 days prior to the first dose.
  8. Female patients of must agree to use highly effective from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
  9. Have a expected survival ≥ 3 months.
  10. Have ability and willingness to comply with protocol-specified visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Have prior treatment with an agent targeting HER3.
  2. Have prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
  3. Have been enrolled in another clinical study concurrently unless it is an observational clinical study or in the follow-up phase of an interventional study.
  4. Have insufficient for prior anticancer therapy prior to first dose of the study drug.
  5. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
  6. Have prior bone marrow transplant or prior solid organ transplant.
  7. Have received treatment with systemic .
  8. Have received any within 4 weeks prior to the first dose of study drug or intend to receive a live vaccine during the study.
  9. or carcinomatous meningitis, spinal cord compression.
  10. with the exceptions.
  11. Have uncontrolled or cardiovascular and cerebrovascular disease.
  12. Have clinically significant concomitant pulmonary diseases.
  13. Have a diagnosis of Gilbert's syndrome.
  14. Have pleural effusion, abdominal effusion.
  15. Have a history of gastrointestinal perforation and or fistula within 6 months prior to the first dose.
  16. Have serious infection.
  17. Patients with (HIV) infection.
  18. Have active virus (HBV) or virus (HCV) infection.
  19. Have any other primary within 5 years prior to the first dose of study drug.
  20. Have unresolved toxicities from prior anticancer therapy.
  21. Have a history of severe reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.
  22. Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Experimental: Corhort A

    YL202 is provided as the lyophilized powder, 200 mg/vial. Triple-negative breast cancer (TNBC) patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

    Drug: YL202 should be intravenously infused

  • Experimental
    Experimental: Corhort B

    YL202 is provided as the lyophilized powder, 200 mg/vial. HR-positive breast cancer with HER2-Zero-expression and HER2-Low-expression patients will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

    Drug: YL202 should be intravenously infused

  • Experimental
    Experimental: Corhort C

    YL202 is provided as the lyophilized powder, 200 mg/vial. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC (excluding HER2+ patients, ie, HER2 IHC 3+ or IHC 2+/ISH+ patients) will be given YL202 by intravenously once every 3 weeks (Q3W) as a cycle.

    Drug: YL202 should be intravenously infused

Interventions

06

What researchers measure

Primary outcomes

  1. ORR assessed according to RECIST v1.1

    ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).

    Time frame: By the end of trial date, approximately within 36 months

  2. Determination of the recommended dose of YL202 in the pivotal clinical study

    Time frame: By the end of trial date, approximately within 36 months

Secondary outcomes

  1. Progression-free survival (PFS) assessed according to RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  2. Clinical benefit rate (CBR) assessed based on RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  3. Depth of response (DpR) assessed based on RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  4. Disease control rate (DCR) assessed based on RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  5. Duration of response (DOR) assessed based on RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  6. Time to response (TTR) assessed based on RECIST v1.1

    Time frame: By the end of trial date, approximately within 36 months

  7. Evaluate the overall survival (OS)

    Time frame: By the end of trial date, approximately within 36 months

  8. Adverse event (AE), described in terms of type, frequency, severity, time, and relationship with study treatment

    Time frame: Approximately within 36 months

  9. Characterize the PK parameter AUC

    steady-state area under curve (AUC)

    Time frame: Approximately within 36 months

  10. Characterize the PK parameter Cmax

    peak concentration (Cmax)

    Time frame: Approximately within 36 months

  11. Characterize the PK parameter Ctrough

    trough concentration (Ctrough)

    Time frame: Approximately within 36 months

  12. Characterize the PK parameter CL

    clearance (CL)

    Time frame: Approximately within 36 months

  13. Characterize the PK parameter Vd

    volume of distribution (Vd)

    Time frame: Approximately within 36 months

  14. Characterize the PK parameter t1/2

    half-life (t1/2)

    Time frame: Approximately within 36 months

  15. Incidence of anti-YL202 antibody

    Time frame: Approximately within 36 months

  16. Evaluate the corelaton between different levels of HER3 expression and the sum of CR rate, PR rate and SD rate

    Time frame: Approximately within 36 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 39 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
Jun 3, 2024
StartActual
Apr 23, 2024
Primary completionEst.
Jul 30, 2027was Jul 2026
CompletionEst.
Jul 29, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 30, 2026→Jul 30, 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Jul 30, 2026→Jul 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06439771
Responsible party
Sponsor
First posted
Jun 3, 2024
Start date
Apr 23, 2024
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 29, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

MediLink Study Team
Contact
clinicaltrials@medilinkthera.com
+86 512 62858368

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beruzatatug pelitecan

Start the discussion